NuCana Presents NUC-7738 Clinical Data at ESMO Congress
NuCana presented the latest clinical data at the annual European Society for Medical Oncology, ESMO, Immuno-Oncology Congress, December 10-12, 2025, in London. The data from patients with PD-1 inhibitor-resistant metastatic melanoma treated with NUC-7738 in combination with pembrolizumab continue to demonstrate clinical activity and a favorable safety profile. All patients had progressive disease prior to starting treatment. Clinical activity includes two partial responses and seven cases of stable disease, notably including one ongoing stable disease converting to a complete metabolic response with no detectable active disease. These results further reinforce the initial findings presented at the ESMO Congress 2024.
Trade with 70% Backtested Accuracy
Analyst Views on NCNA
About NCNA
About the author
Major Stocks Including IBEX, Tesla, IonQ, and Warner Bros. Discovery Rise on Friday
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones index dropping over 100 points on Friday, while several companies, including IBEX Limited, saw significant gains after reporting strong financial results.
IBEX Limited's Financial Success: IBEX Limited's shares surged 33.7% to $40.74 after reporting quarterly earnings of 87 cents per share, exceeding analyst expectations, and providing optimistic sales guidance for FY26.
NuCana Gets Compliance Notice from Nasdaq
Compliance Notification: NuCana has received formal notification from Nasdaq confirming compliance with all continued listing criteria, including the $1.00 minimum bid price requirement.
Stock Performance: Following the announcement, NuCana's stock (NCNA) rose by 2.44% in premarket trading, reaching a price of $2.93.
